Regeneron

-$8.52 (-1.46%) Today
$0.00 (0.00%) As of 9:10 PM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Regeneron and other ETFs, options, and stocks.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.

CEO
Leonard S. Schleifer
Employees
9,123
Headquarters
Tarrytown, New York
Founded
1988

REGN Key Statistics

Market Cap
61.22B
Price-Earnings Ratio
16.50
Dividend Yield
—
Average Volume
573.38K
High Today
$583.27
Low Today
$572.96
Open Price
$581.42
Volume
775.38K
52 Week High
$660.00
52 Week Low
$441.00

REGN News

Reuters3h

FDA okays Regeneron COVID-19 antibody as preventive in high-risk settings

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Br
BenzingaJul 29

Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have announced topline results from Phase 3 trial evaluating Dupixent (dupilumab) in
MarketWatchJul 29

Regeneron, Sanofi: Dupixent Hits Endpoints in Chronic Spontaneous Urticaria

By Colin Kellaher Regeneron Pharmaceuticals Inc. and Sanofi SA Thursday said a pivotal Phase 3 study of their blockbuster eczema drug Dupixent met its primary

REGN Earnings

$0.00
$3.30
$6.59
$9.89
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Available Aug 5, Pre-Market

More REGN News

ABC NewsJul 29

Antibody cocktail may be answer for uncommon breakthrough COVID cases that put some at risk

While authorized vaccines have proven safe and effective in holding the line against COVID-19, they are not 100% effective. Reports of uncommon breakthrough cas
MarketWatchJul 27

Regeneron, AstraZeneca to develop obesity treatment

Shares of Regeneron Pharmaceuticals Inc. REGN, -1.46% were down 0.1% in premarket trading on Tuesday after the company announced a deal with AstraZeneca AZN, -2
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure